NURIX THERAPEUTICS, INC. Increase (Decrease) in Income Taxes Receivable
NURIX THERAPEUTICS, INC. (NRIX) reported Increase (Decrease) in Income Taxes Receivable of $0 for the 12-month period ending 2022-11-30, per its 10-K filed 2023-02-09.
Discontinued › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInIncomeTaxesReceivable · last filed 2023-02-09
- NURIX THERAPEUTICS, INC. increase (decrease) in income taxes receivable for the quarter ending 2021-11-30 was $0.00.
- NURIX THERAPEUTICS, INC. increase (decrease) in income taxes receivable for the quarter ending 2021-08-31 was -$2.94M.
- NURIX THERAPEUTICS, INC. increase (decrease) in income taxes receivable for the quarter ending 2021-05-31 was -$839.00K.
- NURIX THERAPEUTICS, INC. increase (decrease) in income taxes receivable for the quarter ending 2021-02-28 was $135.00K.
- NURIX THERAPEUTICS, INC. increase (decrease) in income taxes receivable for fiscal 2022 was $0.00.
- NURIX THERAPEUTICS, INC. increase (decrease) in income taxes receivable for fiscal 2021 was -$3.64M, a 194.70% decline from fiscal 2020.
- NURIX THERAPEUTICS, INC. increase (decrease) in income taxes receivable for fiscal 2020 was $3.85M.
| Period end | Increase (Decrease) in Income Taxes Receivable 3 month | Increase (Decrease) in Income Taxes Receivable 6 month | Increase (Decrease) in Income Taxes Receivable 9 month | Increase (Decrease) in Income Taxes Receivable 12 month |
|---|---|---|---|---|
| 2022-11-30 | $0.00 10-K · filed 2023-02-09 | |||
| 2021-11-30 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-09 | -$2.94M derived: sum of 2 quarters · filed 2023-02-09 | -$3.78M derived: sum of 3 quarters · filed 2023-02-09 | -$3.64M 10-K · filed 2023-02-09 |
| 2021-08-31 | -$2.94M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-10-06 | -$3.78M derived: sum of 2 quarters · filed 2022-10-06 | -$3.64M 10-Q · filed 2022-10-06 | -$3.65M derived: sum of 4 quarters · filed 2022-10-06 |
| 2021-05-31 | -$839.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2022-07-07 | -$704.00K 10-Q · filed 2022-07-07 | -$714.00K derived: sum of 3 quarters · filed 2022-07-07 | -$16.45M derived: sum of 4 quarters · filed 2022-07-07 |
| 2021-02-28 | $135.00K 10-Q · filed 2022-04-08 | $125.00K derived: sum of 2 quarters · filed 2022-04-08 | -$15.61M derived: sum of 3 quarters · filed 2022-04-08 | |
| 2020-11-30 | -$10.00K derived: 10-K 12 month − 10-Q 9 month · filed 2022-01-28 | -$15.74M derived: sum of 2 quarters · filed 2022-01-28 | $3.85M 10-K · filed 2022-01-28 | |
| 2020-08-31 | -$15.73M derived: 10-Q 9 month − 10-Q 6 month · filed 2021-10-14 | $3.86M 10-Q · filed 2021-10-14 | ||
| 2020-05-31 | $19.59M 10-Q · filed 2021-07-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| SELLAS Life Sciences Group, Inc. (SLS) | United States | $2.420B | -91.87 |
| uniQure N.V. (QURE) | $2.416B | -4.93 | |
| Vera Therapeutics, Inc. (VERA) | United States | $2.402B | -7.67 |
| Harmony Biosciences Holdings, Inc. (HRMY) | United States | $2.399B | 11.67 |
| SUPERNUS PHARMACEUTICALS, INC. (SUPN) | United States | $2.517B | -24.63 |
| Immunome Inc. (IMNM) | United States | $2.538B | -9.45 |
| Disc Medicine, Inc. (IRON) | United States | $2.553B | -11.40 |
| Mineralys Therapeutics, Inc. (MLYS) | United States | $2.353B | -6.82 |
| Viridian Therapeutics, Inc.\DE (VRDN) | United States | $2.342B | -5.38 |
| MBX Biosciences, Inc. (MBX) | United States | $2.664B | -25.36 |